In Brief: Boston Life Sciences
This article was originally published in The Gray Sheet
Executive Summary
Boston Life Sciences: Initial studies of the firm's Altropane imaging agent for rapid single photon emission computerized tomography (SPECT) scan diagnosis of Parkinson's disease show the agent "allows for accurate diagnosis of Parkinson's disease in less than two hours after injection," the firm states in a June 5 release. Studies of 15 subjects, including seven healthy patients and eight Parkinson's patients, were presented at the annual Society of Nuclear Medicine meeting in San Antonio, Texas during the week of June 2. The studies "demonstrated that Altropane accumulated rapidly and selectively in the dopamine transporters" of healthy patient brains and that accumulation "was markedly reduced" in Parkinson's patients, the firm says...
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.